Mayo Clinic is committed to taking care of our patients, learners and staff. Due to the COVID-19 pandemic, Mayo Clinic Department of Cardiovascular Medicine education is suspending live courses and conferences through December 31, 2020. Please continue to check our website as we shift to meeting our learner needs by providing virtual and on-demand offerings. We will continue to closely monitor future 2021 live courses as the CDC makes further recommendations and also invite you to review more information on Mayo Clinic COVID Resources.

Cardiovascular Conference at Snowbird

February 9-12, 2021
Cliff Lodge, Snowbird, Utah

Registration Opening Soon
Credit Types: AMA PRA Category 1 (18.5), MOC (18.5), | Price: $795 - $895 | Early Registration Saves $100

Program

Tuesday, February 9
6:45 a.m.
Registration and Continental Breakfast
7:20 a.m.
Welcome and Course Introduction - Course Directors
HEART FAILURE MANAGEMENT
Moderator: Douglas Packer, MD
7:30 a.m.
Acute Heart Failure: Why Am I Still Short of Breath?
Clyde Yancy, MD
7:50 a.m.
Heart Failure With Reduced Ejection Fraction (HFrEF): What is Optimal Medical Therapy in 2021?
Robert Frantz, MD
8:10 a.m.
Chronic HFpEF and Restrictive Cardiomyopathies
8:30 a.m.
When Epidemics Collide: HFpEF and Obesity
Grace Lin, MD
8:50 a.m.
Atrial Fibrillation and Heart Failure: Does HF Benefit from AF Ablation?
Douglas Packer, MD
9:10 a.m.
Should New Drugs Be First Line Therapy? Will Biomarkers Tell Us How to Treat?
Clyde Yancy, MD
9:30 a.m.
Questions and Answers
9:45 a.m.
Adjourn - Afternoon Session at 4:00 pm
3:45 p.m.
Apres-Ski Snacks
SPECIAL TOPICS
Moderator: Bernard Gersh, MB, ChB, DPhil
4:00 p.m.
Optimizing Medical Therapy and Following the Guidelines
Clyde Yancy, MD
4:20 p.m.
Advanced Heart Failure: Current Strategies
Robert Frantz, MD
4:40 p.m.
Cardiology, Oncology, and Radiation Oncology
Grace Lin, MD
5:00 p.m.
Cardiomyopathies and Infiltrative Culprits: Amyloid, Sarcoid, and Hypereosinophilia
Clyde Yancy, MD
5:20 p.m.
HF and Devices
Grace Lin, MD
5:40 p.m.
Palliative Care in Heart Disease
Grace Lin, MD
6:00 p.m.
Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Pathophysiology and Management
Bernard Gersh, MB, ChB, DPhil
6:20 p.m.
Questions and Answers
6:45 p.m.
Adjourn
Wednesday, February 10
7:00 a.m.
Continental Breakfast - Visit Exhibits
RHYTHM DISORDERS AND THEIR MANAGEMENT
Moderator: Douglas Packer, MD
7:30 a.m.
ECG Clues for AF, AFL, SVT, and Other Arrhythmias
George Klein, MD
7:50 a.m.
Atrial Fibrillation Diagnosis and Management
Peter Noseworthy, MD
8:10 a.m.
Atrial Fibrillation as a Vascular Disease: The Role of Up Stream Therapy
Bernard Gersh, MB, ChB, DPhil
8:30 a.m.
Anticoagulation for Atrial Fibrillation
Christopher Granger, MD
8:50 a.m.
To Ablate or Not? News From CABANA, EAST, and DECAFFEII
Douglas Packer, MD
9:10 a.m.
Questions and Answers
9:30 a.m.
Adjourn - Afternoon Session at 4:00 pm
3:45 p.m.
Après-Ski Snacks
SPECIAL TOPICS
Moderator: Douglas Packer, MD
4:00 p.m.
Sleep Apnea and Atrial Fibrillation
Peter Noseworthy, MD
4:20 p.m.
Risk Stratification for Stroke in Atrial Fibrillation
Bernard Gersh, MB, ChB, DPhil
4:40 p.m.
VT and VF: Considerations for Appropriate Treatment
Peter Noseworthy, MD
5:00 p.m.
Common Problems With Pacemakers and Defibrillators and How to Recognize Them
George Klein, MD
5:20 p.m.
Articificial Intelligence: What Is on the Horizon?
Peter Noseworthy, MD
6:00 p.m.
Left Atrial Appendage Closure – What a Cardiologist Needs to Know
Douglas Packer, MD
6:45 p.m.
Adjourn
Thursday, February 11
7:00 a.m.
Continental Breakfast - Visit Exhibits
STRUCTURAL HEART DISEASE
Moderator: Bernard Gersh, MB, ChB, DPhil
7:30 a.m.
What’s New and What’s Likely to Be Controversial in Valvular Heart Disease Guidelines
Blase Carabello, MD
7:50 a.m.
Pathophysiology and Management of Functional Mitral Regurgitation: Evolving Concepts
Bernard Gersh, MB, ChB, DPhil
8:10 a.m.
Novel Percutaneous Approaches to Mitral Regurgitation
8:30 a.m.
Tricuspid Valve Regurgitation: Assessment and Advances in Treatment
Sabrina Phillips, MD
8:50 a.m.
Is Trans-aortic Valve Replacement (TAVR) Ready for All Patients?
Blase Carabello, MD
9:10 a.m.
Relationship Between Atrial Fibrillation and MR/TR: Chicken or Egg
Douglas Packer, MD
9:30 a.m.
Questions and Answers
9:45 a.m.
Adjourn - Afternoon Session at 4:00 pm
3:45 p.m.
Apres-Ski Snacks
STRUCTURAL HEART DISEASE AND SPECIAL TOPICS
Moderator: Sabrina Phillips, MD
4:00 p.m.
The Five Most Important Trials in Valvular Heart Disease
Blase Carabello, MD
4:20 p.m.
Imaging for Heart Valve Disease
Grace Lin, MD
4:40 p.m.
Managing Cryptogenic Stroke: The Role of the Cardiologist
Christopher Granger, MD
5:00 p.m.
Cryptogenic Stroke: Embolic Stroke of Undetermined Source (ESUS) and PFO
James Klaas, MD
5:20 p.m.
PFO and Atrial Septal Defect: When They Need to Be Closed
Sabrina Phillips, MD
5:40 p.m.
The Echo Says My Patient Has Pulmonary Hypertension: What Do I Do Now?
Robert Frantz, MD
6:00 p.m.
Adult Congenital Heart Disease: What to Consider In the Office.
Sabrina Phillips, MD
6:20 p.m.
Questions and Answers
6:45 p.m.
Adjourn & Dinner - Participants, Faculty and Guests are invited. (Primrose Room, Lobby Level)
Friday, February 12
6:45 a.m.
Continental Breakfast
PREVENTIVE CARDIOLOGY AND ISCHEMIC HEART DISEASE
Moderator: Jeffrey Anderson, MD
7:00 a.m.
Emerging Cardiovascular Risk Factors and Innovative Treatments
Jeffrey Anderson, MD
7:25 a.m.
Diabetes and CVD: What is the Optimal Approach for Integrated Management With the Newer Agents
R. Scott Wright, MD
7:50 a.m.
Genetics and Cardiovascular Disease
Jeffrey Anderson, MD
8:15 a.m.
New Strategies to Lower LDL-C
R. Scott Wright, MD
8:40 a.m.
Acute Coronary Syndromes (ACS)
Christopher Granger, MD
9:05 a.m.
The Role of Coronary Revascularization in Patients With Severe LV Dysfunction: Is Viability Testing Still Viable
Bernard Gersh, MB, ChB, DPhil
9:30 a.m.
Antithrombotic Therapy for Patients With Vascular Disease
Christopher Granger, MD
9:55 a.m.
Chronic Total Occlusions – Too Many or Too Few Interventions?
10:20 a.m.
Neurological Complications of Coronary Revascularization, Cardiac Surgery, and AF Ablation
James Klaas, MD
10:35 a.m.
Statins and Beyond: Helping You Choose Wisely Among Alternatives to Reduce Lipids
R. Scott Wright, MD
11:00 a.m.
Questions and Answers
11:10 a.m.
Closing Comments
11:15 a.m.
Adjourn
Credit Types Offered
  • AMA PRA Category 1
    18.5
  • MOC
    18.5

Price: $795 - $895 | Early Registration Saves $100

Live Courses

Back to Top